Salvage Palmar Fasciectomy Following Initial Treatment with Collagenase Clostridium Histolyticum

Kyle R. Eberlin MD, Edward M. Kobraei MD, Jacob Bloom MD, Joseph Upton III MD

**BACKGROUND**
- Collagenase clostridium histolyticum (CCH) was approved for use in Dupuytren's in 2010
- Because longitudinal experience with CCH remains limited, the effect of treatment on future surgery is not well defined
- We have noticed increased operative difficulty of fasciectomy following CCH injection

**METHODS**
- A retrospective review was performed from February 2010 to March 2014
- 11 patients identified who underwent complete palmar fasciectomy following at least one prior CCH injection
- Cases reviewed for functional outcomes and operative difficulty

**RESULTS**
- 7 MCP and 12 PIP joints treated in 11 patients
- Average interval between most recent CCH injection and salvage fasciectomy was 12 months
- Intraoperative findings demonstrated disruption of normal tissue architecture and extensive scarring
- Mean pre- and post-operative contractures for MP joints were 42 and 0 degrees; PIP joints 60 and 21 degrees

**CONCLUSIONS**
- CCH injection may produce extensive scarring and increase the difficulty of salvage fasciectomy
- With careful technique, results of salvage fasciectomy may be similar to primary surgery